[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642447":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":35,"collaborators":25,"id":39,"slug":25,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":25,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":25,"enrollmentInfo":47,"targetDuration":25,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":25,"overallStatus":58,"whyStopped":25,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":25},{"fullName":5,"class":6},"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nicardipine Group","EXPERIMENTAL","Nicardipine infusion administered to achieve controlled hypotension (target MAP 55-65 mmHg) under general anesthesia prior to elective nasal surgery. Standard institutional protocol applied.",[13],"Drug: Nicardipine",{"label":15,"type":16,"description":17,"interventionNames":18},"Remifentanil Group","ACTIVE_COMPARATOR","Remifentanil infusion administered to achieve controlled hypotension (target MAP 55-65 mmHg) under general anesthesia prior to elective nasal surgery. Standard institutional protocol applied.",[19],"Drug: Remifentanil",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Nicardipine",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Remifentanil",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Fikret Salık","CONTACT","+905076214125","fikretsalik@gmail.com",{"type":36,"investigatorFullName":31,"investigatorTitle":37,"investigatorAffiliation":38,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Medicine Doctor Associate Professor in Anesthesiology","Dicle University","100642447",false,"NCT07660562","Remifentanil vs. Nicardipine for Controlled Hypotension in Elective Nasal Surgery","Comparison of Remifentanil and Nicardipine Infusions for Controlled Hypotension in Elective Nasal Surgery Where Bleeding Control is Critical: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\> 18 years\n* ASA physical status I-II\n* Scheduled for elective nasal surgery\n* No known serious cardiovascular, respiratory, renal, or hepatic disease\n* No known allergy to remifentanil or nicardipine\n* No chronic use of beta-blockers, calcium channel blockers, or antihypertensive agents\n* Not pregnant or breastfeeding\n* BMI ≤ 35 kg\u002Fm²\n* No emergency surgical indication\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* ASA III or above\n* Known serious cardiovascular, respiratory, renal, or hepatic disease\n* Known allergy to remifentanil or nicardipine\n* Chronic use of beta-blockers, calcium channel blockers, or antihypertensive agents\n* Pregnancy or breastfeeding\n* Morbid obesity (BMI \\> 35 kg\u002Fm²)\n* Emergency surgery\n* Refusal to participate","ALL","18 Years",{"count":48,"type":49},44,"ESTIMATED","INTERVENTIONAL",[52],"NA","This study compares remifentanil infusion versus nicardipine infusion for controlled hypotension during elective nasal surgery. Both agents are standard clinical methods. The study evaluates hemodynamic stability, surgical field quality (Fromme-Boezaart score), tissue perfusion, intraoperative blood loss, surgeon satisfaction, and perioperative adverse effects.",[55,56,57],"Nasal Surgery","Anesthesia","Controlled Hypotension for Nasal Surgeries","NOT_YET_RECRUITING","2026-06-16",{"date":61,"type":62},"2026-06-22","ACTUAL",{"date":64,"type":49},"2026-06-25",{"date":66,"type":49},"2026-07-15",{"name":5,"class":6}]